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Characterization of HIV-1 Integrase Interactions with Viral DNA 
Figure 4. Integrase binding to DNA, as measured by quartz crystal 
microbalance. Quartz crystal microbalance sensors were functionalized with  
duplex DNA.  Reaction components were flowed over sensors, and change in 
resonance frequency was measured.  Reaction conditions were 20 mM Mops, 
pH 7.2, 5 mM NaCl, 7.5 mM MnCl2, 200-500 mM HIV-1 integrase.  21-mer thiol 
duplex DNA was bound to the sensor surface, and the concentration is 
unknown.   
 
Results:  The drop in frequency with addition of integrase-containing buffer 
indicates integrase binding of integrase to DNA.  We are currently replicating 
this result and will use this data to calculate a dissociation constant between 
integrase and DNA. 
 
Figure 3.   The effect of reaction component pre-incubation on 3’-
processing and strand transfer.  Reaction conditions were 20 mM Mops, pH 
7.2, 5 mM NaCl, 14.3 mM b-mecaptoethanol, 7.5 mM MnCl2, 1 μM integrase, 
and 20 nM 21-mer duplex DNA.  This experiment tested the effect of pre-
integration of DNA and HIV-1 integrase on formation of reaction products.  
Metal was added after the pre-incubation, to start the reaction.  The left and 
the right panels show reaction products after 0 minutes of preincubation or 30 
minutes of preincubation on ice, respectively.  3’-processing (dark grey bars) 
and strand transfer (light gray bars) reaction products were quantified using 
ImageQuant software. 
 
Results:  Pre-incubation of 20nM 21-mer duplex DNA and 1 μM HIV-1 
integrase had no substantial overall effect on 3’ processing and strand transfer 
when manganese was used as a cofactor. An increase in 3’ processing was 
seen when magnesium was the metal cofactor. 
Figure 2.  The effect of sodium chloride concentration on 3’-processing 
and strand transfer.  Reaction conditions are 20 mM Mops, pH 7.2, 0 (left 
panels) or 5 (right panels) mM NaCl, 14.3 mM b-mecaptoethanol, 7.5 mM 
MnCl2, 1 μM HIV-1 integrase, and 20 nM 21-mer duplex DNA.  Two integrase 
preparations were compared: 7/5/12 (top panels) and 7/9/12 (bottom panels).  
3’-processing (dark grey bars) and strand transfer (light gray bars) reaction 
products were quantified using ImageQuant software.  
 
Results:  Levels of 3’ processing and strand transfer are consistent with 
previous studies.  Manganese exhibits higher product percentages, although 
magnesium is the in-vivo metal cofactor.  
 
Figure 1. In vitro catalytic assay of HIV-1 Integrase. (a.) Diagram of an 
assay that represents the catalytic steps resulting in HIV-1 genome 
integration into host cell.  The 21 base pair substrate DNA is derived from 
the end of HIV-1 viral DNA sequence.  Integrase 3’-processing occurs when 
the enzyme recognizes and binds to a conserved nucleotide sequence (5’-
CAGT-3’) at the DNA end.  Integrase cleaves the terminal dinucleotide (5’-
GT-3’), leaving a 3’-OH group that can subsequently attack a phosphodiester 
bond in the target (host) DNA to achieve strand transfer. (b.) In vitro reaction 
products visualized by gel electrophoresis.  DNA is 32P-labeled on the 5’ end 
of the cleaved strand. Reaction conditions are 20 mM Mops, pH 7.2, 5 mM 
NaCl, 14.3 mM -mercaptoethanol, 7.5 mM MnCl2, 1 mm integrase, and 20 
nM 21-mer DNA duplex. Samples are incubated for 60 minutes at 37oC.  
Lane 1. No integrase.  Lane 2. with 1μM HIV-1 integrase. The 3’-P and 
strand transfer products are labeled. 
ABSTRACT 
HIV-1 integrase (integrase) catalyzes the insertion of viral DNA 
into human chromosomes and is a focus for development of anti-
integrase inhibitors to combat HIV infection.  Integrase catalyzes 
two steps, a DNA-end cleavage reaction (3’-processing), and a 
DNA-end joining reaction (strand transfer). Together, these steps 
result in viral DNA integration into the genome of the host cell, 
resulting in persistent infection.  Better understanding of the 
mechanism of integration and interactions of the viral and host 
DNA with integrase are required for optimal inhibitor 
development.  Recombinant integrase protein was purified and 
activity was evaluated in a biochemistry assay under bulk 
conditions to optimize 3’-processing and strand transfer activity.  
Integrase binding to DNA was then measured under these 
conditions, using quartz crystal microbalance.  This technique will 
also be used to characterize the disruption of integrase binding to 
DNA by inhibitors.  Finally, integrase/DNA complexes will be 
visualized by atomic force microscopy to explore their interaction.  
This study addresses gaps in knowledge of viral DNA and HIV-1 
integrase interactions as well as the effects of inhibitors on DNA 
binding. 
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INTRODUCTION 
Since its discovery in 1981, HIV/AIDS has become a world-wide 
epidemic.  More than 25 million people have died and over 34 
million people are currently infected (WHO Factsheet No. 360).  
Treatment includes a triple therapy “cocktail” of drugs.  These 
drugs include a protease inhibitor (PI) or a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) in combination with two 
nucleoside reverse transcriptase inhibitors (NRTI).  Together, 
these drugs target all steps of the viral life cycle: reverse 
transcription, proteolytic maturation, integration, and fusion 
(Summa 2008).  This has increased the median length of survival 
to eight years, up from one year of survival after diagnosis in 
1987.  However, this drug treatment program requires strict 
adherence and is not a cure for viral infection.  Due to the rapidly 
mutating nature of the virus, drug resistance often occurs.  
Recently, an inhibitor drug targeting HIV-1 integrase was added 
to HIV/AIDS drug treatment, providing one more method to 
combat the virus.  Further research of HIV-1 integrase and 
inhibitors targeting the enzyme will help create more effective 
treatment (Cocohoba 2008). 
Human Immunodeficiency Virus-1 (HIV-1) integrase is the viral 
protein responsible for catalyzing the insertion of viral DNA into 
human chromosomes.  Integrase binds both ends of the linear 
viral DNA as well as the host chromosomal DNA, resulting in 
integration.  Once integration occurs, the human cell harbors the 
HIV genome, resulting in chronic infection.  Development of 
efficient integrase inhibitors has been hampered by poor 
understanding of structure and function of the enzyme (Guiot 
2006).  The three-dimensional structure of the full-length protein 
has been difficult to resolve either in the presence or absence of 
a viral DNA substrate, limiting understanding of the interactions 
between HIV-1 integrase and DNA.  This study will address gaps 
in knowledge of viral DNA and HIV-1 integrase interaction as well 
as the effects of inhibitors on DNA binding (Pommier 2005). 
 
PROJECT GOALS 
• Purify recombinant integrase protein 
• Verify integrase activity by catalytic assay 
• Measure interaction of integrase and DNA by quartz crystal 
microbalance 
• Image interaction of integrase and DNA by atomic force 
microscopy 
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METHODS 
Purification 
HIV-1 integrase was expressed from a plasmid in an 
Escherichia coli expression system, and purified using 
chelating nickel chromatography. Protein was eluted with 
increasing concentrations of imidazole.  Purified protein was 
visualized by SDS-poly acrylamide gel electrophoresis, and 
desired fractions were dialyzed into storage buffer overnight. 
Generally, 300 mg of protein was obtained from several rounds 
of purification.  Purity was estimated at ~95% after SDS-Page 
gel electrophoresis of the purified protein product.  Protein was 
aliquoted and stored at 800C. 
  
Catalytic assay 
Integrase (1 μM) was incubated with DNA (20 nM 21base pair 
duplex substrate) substrates for 1h at 37°C. This high 
concentration of integrase was used to maintain the multimer 
complex required for enzymatic activity. Reactions were 
quenched by the addition of an equal volume of gel loading dye 
containing formamide. Products were separated on 20% 
polyacrylamide denaturing sequencing gels. Gels were 
visualized using a Molecular Dynamics 445 SI phosphorimager.  
Densitometric analysis was performed using ImageQuant 
software. 
 
QCM  
Quartz Crystal Microbalance Q-Sense E4 gold sensors (Biolin 
Scientific, Inc.) were cleaned with UV/ozone, ethanol, and 
RNAse-free water.  Sensors were then functionalized by 
immersion of 5 μM solution thiolated DNA duplex (H6-C6-DNA 
duplex) reaction buffer for 2h. Unlinked DNA duplexes were 
removed from sensor by gentle washing with reaction buffer.  
Sensor was placed in a QCM module and equilibrated with 
reaction buffer at 10 μl/min.  Reaction buffer was added 
containing HIV-1 integrase (200 nM, 500 nM, and 1 μM) at 10 
μL/min until stabilization of frequency. 
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RESULTS 
•HIV-1 assays exhibit 3’ processing and strand transfer 
percentages consistent with previous studies 
•Preliminary studies suggest an increase in binding activity 
with an increase in enzyme concentration. 
•Further studies will visualize the DNA-enzyme complex 
using Atomic Force Microscopy to measure the binding 
affinity of HIV-1  
 
